Dublin, April 26, 2021 (GLOBE NEWSWIRE) -- The "Global Actinic Keratosis Treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.
The actinic keratosis treatment market is anticipated to showcase a considerable growth rate during the forecast period. The rising prevalence and incidence of actinic keratosis treatment along with the rising development of novel approaches for the treatment of actinic keratosis is anticipated to be a key factor contributing to the growth of the market.
The actinic keratosis treatment market is segmented based on type, and end-user. Based on the type, the market is segmented into medication, therapy, and other (combination therapy). Medication to showcase considerable growth based on treatment type. The growing FDA approval for the new drugs to treat actinic keratosis is anticipated to drive the growth of this market segment. Based on medication, the market is segmented into fluorouracil, imiquimod, ingenol mebutate, others. Based on therapy, the market is segmented into photodynamic therapy and LASER surgery. Based on end-user, the market is segmented into hospitals & oncology centers, and dermatology clinics.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a considerable market share in the actinic keratosis treatment market due to the high awareness of the drugs for the treatment of actinic keratosis treatment in the region. Asia-Pacific is the fastest-growing region in the market. The increasing prevalence of skin disorders in the emerging economies of Asia-Pacific is a key factor contributing to the growth of the market in the region.
The key players in the actinic keratosis treatment market include Bausch Health Companies, Inc., Biofrontera AG, BioLineRx, Ltd., Cipher Pharmaceuticals, Inc., Galderma SA, Hill Dermaceuticals, Inc., LEO Pharma A/S, Valeant Pharmaceuticals Inc., and so on. The major players of the market are making hefty investments in the R&D of new drugs and therapies. The continuous efforts of the market players in the development of new drugs and therapies are driving the growth of the global market.
The market study of the global actinic keratosis treatment market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
Financial reports of companies involved in the market.
Whitepapers, research-papers, and news blogs.
Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
1. Global Actinic Keratosis Treatment Market Research and Analysis by Type
2. Global Actinic Keratosis Treatment Market Research and Analysis by End-User
The Report Covers:
Comprehensive research methodology of the global actinic keratosis treatment market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global actinic keratosis treatment market.
Insights about market determinants that are stimulating the global actinic keratosis treatment market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. LEO Pharma A/S
18.104.22.168. Financial Analysis
22.214.171.124. SWOT Analysis
126.96.36.199. Recent Developments
3.3.2. Biofrontera AG
188.8.131.52. Financial Analysis
184.108.40.206. SWOT Analysis
220.127.116.11. Recent Developments
3.3.3. Sun Pharmaceuticals Industries, Ltd.
18.104.22.168. Financial Analysis
22.214.171.124. SWOT Analysis
126.96.36.199. Recent Developments
3.3.4. 3M Co.
188.8.131.52. Financial Analysis
184.108.40.206. SWOT Analysis
220.127.116.11. Recent Developments
3.3.5. Galderma S.A.
18.104.22.168. Financial Analysis
22.214.171.124. SWOT Analysis
126.96.36.199. Recent Developments
4. Market Determinants
5. Market Segmentation
5.1. Global Actinic Keratosis Treatment Market by Type
188.8.131.52. Ingenol Mebutate
184.108.40.206. Photodynamic Therapy
220.127.116.11. Laser Surgery
5.1.3. Others (Combination Therapy)
5.2. Global Actinic Keratosis Treatment Market by End-User
5.2.1. Hospitals & Oncology Centers
5.2.2. Dermatology Clinics
6. Regional Analysis
6.1. North America
6.2.6. Rest of Europe
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. 3M Co.
7.2. Alma Lasers, Inc.
7.3. Almirall, S.A.
7.4. Bausch Health Companies Inc.
7.5. Biofrontera AG
7.6. BioLineRx, Ltd.
7.7. Cipher Pharmaceuticals, Inc.
7.8. Galderma S.A.
7.9. Hill Dermaceuticals, Inc.
7.10. LEO Pharma A/S
7.11. Mylan N.V.
7.12. Stanford Chemicals Company
7.13. Sun Pharmaceutical Industries, Ltd.
7.14. Teva Pharmaceutical Industries, Ltd.
7.15. Valeant Pharmaceuticals, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/bc531q
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900